Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Consulting agrmnt
|
|
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
8-K
| Investor presentation |
| 06/12/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 05/19/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
8-K/A
| Quarterly results |
| 04/03/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
4
| Ben Yong (Director) has filed a Form 4 on Corbus Pharmaceuticals Holdings, Inc.|
Txns:
| Granted 5,307 options to buy
@ $2.85, valued at
$15.1k
|
|
| 03/07/2023 |
3
| Ben Yong (Director) has filed a Form 3 on Corbus Pharmaceuticals Holdings, Inc. |
| 03/07/2023 |
8-K
| Investor presentation, Quarterly results |
| 03/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/13/2023 |
8-K
| Quarterly results |
| 01/06/2023 |
8-K
| Quarterly results |
| 12/21/2022 |
8-K
| Quarterly results |
| 12/21/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/04/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/31/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT entered into as of October 25, 2022, by and among Corbus Pharmaceuticals, Inc., a Delaware corporation , and each other Person party thereto as a borrower from time to time , Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation , lenders constituting Required Lenders and K2 HEALTHVENTURES LLC, as administrative agent for Lenders . RECITALS A. The parties hereto previously entered into that certain Loan and Security Agreement, dated as of July 28, 2020 , by and among Borrower Representative, Parent, Lenders, Administrative Agent and Ankura Trust Company, LLC, as collateral agent for Lenders . Capitalized terms used but not defined in this Amendment shall have the respective meanings..." |
|
| 10/12/2022 |
8-A12G
| Form 8-A12G - Registration of securities [Section 12(g)]: |
| 10/12/2022 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...|
Docs:
|
"AMENDMENT NO. 2 TO THE AMENDED AND RESTATED BYLAWS OF CORBUS PHARMACEUTICAL HOLDINGS, INC. Article I of the Amended and Restated Bylaws of Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation, as amended to date , is hereby amended as follows: Article I, Section 5 of the Bylaws be, and hereby is, amended to read in its entirety as follows: “SECTION 5. Quorum. Except as specifically provided otherwise by the DGCL, the Certificate of Incorporation, or these Bylaws, the presence, in person or by proxy, of the holders of one-third in voting power of the shares of capital stock issued and outstanding and entitled to vote at a meeting of stockholders of the issued and outstanding shares of Common Stock of the Corporation entitled to vote at the meeting) shall constitute a quorum ...",
"CORBUS PHARMACEUTICALS HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Corbus Pharmaceuticals Holdings, Inc., a Delaware corporation , that the following resolution was duly adopted by the board of directors of the Corporation , in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended , at a meeting duly called and held on October 11, 2022, which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value $0.0001 per share, which is designated as “Series A Preferred Stock,” with the rights, powers and preferences, and the qualifica..." |
|
| 09/28/2022 |
4
| Altmeyer Anne (Director) has filed a Form 4 on Corbus Pharmaceuticals Holdings, Inc.|
Txns:
| Granted 159,200 options to buy
@ $0.16, valued at
$25.5k
|
|
| 09/28/2022 |
3
| Altmeyer Anne (Director) has filed a Form 3 on Corbus Pharmaceuticals Holdings, Inc. |
| 09/26/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/24/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/12/2022 |
4
| Millian Craig Stuart (COO) has filed a Form 4 on Corbus Pharmaceuticals Holdings, Inc.|
Txns:
| Bought 5,000 shares
@ $0.2545, valued at
$1.3k
|
|
| 08/11/2022 |
4
| Cohen Yuval (CEO) has filed a Form 4 on Corbus Pharmaceuticals Holdings, Inc.|
Txns:
| Bought 3,800 shares
@ $0.264, valued at
$1k
|
|
| 08/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|